Next Article in Journal
MicroRNA in United Airway Diseases
Next Article in Special Issue
Drug, Herb, and Dietary Supplement Hepatotoxicity
Previous Article in Journal
Evidence for the Induction of Key Components of the NOTCH Signaling Pathway via Deltamethrin and Azamethiphos Treatment in the Sea Louse Caligus rogercresseyi
Previous Article in Special Issue
Herbal Hepatotoxicity: Clinical Characteristics and Listing Compilation
Review

Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury

1
Unidad de Gestión Clínica de Enfermedades Digestivas y Farmacología Clínica, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, 29071 Málaga, Spain
2
Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Igor P. Pogribny
Int. J. Mol. Sci. 2016, 17(5), 714; https://doi.org/10.3390/ijms17050714
Received: 20 March 2016 / Revised: 26 April 2016 / Accepted: 5 May 2016 / Published: 12 May 2016
(This article belongs to the Special Issue Drug, Herb, and Dietary Supplement Hepatotoxicity)
Idiosyncratic drug-induced liver injury (DILI) caused by xenobiotics (drugs, herbals and dietary supplements) presents with a range of both phenotypes and severity, from acute hepatitis indistinguishable of viral hepatitis to autoimmune syndromes, steatosis or rare chronic vascular syndromes, and from asymptomatic liver test abnormalities to acute liver failure. DILI pathogenesis is complex, depending on the interaction of drug physicochemical properties and host factors. The awareness of risk factors for DILI is arising from the analysis of large databases of DILI cases included in Registries and Consortia networks around the world. These networks are also enabling in-depth phenotyping with the identification of predictors for severe outcome, including acute liver failure and mortality/liver transplantation. Genome wide association studies taking advantage of these large cohorts have identified several alleles from the major histocompatibility complex system indicating a fundamental role of the adaptive immune system in DILI pathogenesis. Correct case definition and characterization is crucial for appropriate phenotyping, which in turn will strengthen sample collection for genotypic and future biomarkers studies. View Full-Text
Keywords: drug-induced liver injury; DILI; risk factors drug-induced liver injury; DILI; risk factors
Show Figures

Graphical abstract

MDPI and ACS Style

Ortega-Alonso, A.; Stephens, C.; Lucena, M.I.; Andrade, R.J. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int. J. Mol. Sci. 2016, 17, 714. https://doi.org/10.3390/ijms17050714

AMA Style

Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. International Journal of Molecular Sciences. 2016; 17(5):714. https://doi.org/10.3390/ijms17050714

Chicago/Turabian Style

Ortega-Alonso, Aida, Camilla Stephens, M. I. Lucena, and Raúl J. Andrade 2016. "Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury" International Journal of Molecular Sciences 17, no. 5: 714. https://doi.org/10.3390/ijms17050714

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop